SAN DIEGO – People with Type 2 diabetes benefit from the use of continuous glucose monitoring, according to a study published recently in the Annals of Internal Medicine by DexCom, a company that makes a CGM system. Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education or math ability. “The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions,” said Dr. Roy Beck, lead study investigator from the Jaeb Center for Health Research, in a statement.